drugset / Trial / NCT06285240

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

NCT06285240

Phase 1 Completed 28 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.

Timeline

Start
2024-03-28
Primary completion
2024-09-23
Completion
2024-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-1167 Unknown 3 mg Oral
Subject MK-1167 Unknown 6 mg Oral
Background Donepezil Small molecule 10 mg Oral

Indications